Who are Lenalidomide and low-dose dexamethasone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PAD combination, VRD for first-cycle induction therapy, Drug: Carfilzomib + Lenalidomide + Dexamethasone, Isatuximab Carfilzomib Lenalidomide Dexamethasone, Bortezomib/Lenalidomide/ Low dose Dex, Bortezomib, cyclophosphamide, thalidomide, dexamethasone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lenalidomide-and-low-dose-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lenalidomide and low-dose dexamethasone — Competitive Intelligence Brief

Lenalidomide and low-dose dexamethasone (Lenalidomide and low-dose dexamethasone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulatory agent + corticosteroid. Area: Oncology.

phase 3 Immunomodulatory agent + corticosteroid Cereblon (CRBN), TNF-α pathway; glucocorticoid receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lenalidomide and low-dose dexamethasone (Lenalidomide and low-dose dexamethasone) — Celgene. Lenalidomide enhances immune cell activity and has anti-angiogenic and anti-proliferative effects, while dexamethasone provides anti-inflammatory and immunosuppressive activity to reduce myeloma cell growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lenalidomide and low-dose dexamethasone TARGET	Lenalidomide and low-dose dexamethasone	Celgene	phase 3	Immunomodulatory agent + corticosteroid	Cereblon (CRBN), TNF-α pathway; glucocorticoid receptor
PAD combination	PAD combination	Cooperative Study Group A for Hematology	marketed	Combination therapy (proteasome inhibitor + immunomodulatory agent + corticosteroid)	26S proteasome; cereblon (CRBN); glucocorticoid receptor
VRD for first-cycle induction therapy	VRD for first-cycle induction therapy	The First Affiliated Hospital of Soochow University	marketed	Proteasome inhibitor + immunomodulatory agent + corticosteroid combination	26S proteasome (bortezomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Drug: Carfilzomib + Lenalidomide + Dexamethasone	Drug: Carfilzomib + Lenalidomide + Dexamethasone	Amgen	marketed	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Isatuximab Carfilzomib Lenalidomide Dexamethasone	Isatuximab Carfilzomib Lenalidomide Dexamethasone	European Myeloma Network B.V.	phase 3	Combination therapy: monoclonal antibody + proteasome inhibitor + immunomodulatory agent + corticosteroid	CD38 (isatuximab); proteasome (carfilzomib); cereblon (lenalidomide); glucocorticoid receptor (dexamethasone)
Bortezomib/Lenalidomide/ Low dose Dex	Bortezomib/Lenalidomide/ Low dose Dex	King Faisal Specialist Hospital & Research Center	phase 3	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	Proteasome (bortezomib); Cereblon (lenalidomide); Glucocorticoid receptor (dexamethasone)
Bortezomib, cyclophosphamide, thalidomide, dexamethasone	Bortezomib, cyclophosphamide, thalidomide, dexamethasone	Grupo de Estudos Multicentricos em Onco-Hematologia	phase 3	Combination chemotherapy regimen (proteasome inhibitor + alkylating agent + immunomodulatory agent + corticosteroid)	Proteasome (bortezomib); DNA (cyclophosphamide); TNF-α pathway and cereblon (thalidomide); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulatory agent + corticosteroid class)

Celgene · 1 drug in this class
IRCCS Centro di Riferimento Oncologico della Basilicata · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lenalidomide and low-dose dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/lenalidomide-and-low-dose-dexamethasone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab